Phase III ROCKET AF Study of Rivaroxaban meets its primary efficacy endpoint with Comparable Safety vs. Warfarin
|
02 November 2010 |
Bayer lifts sales and earnings again
|
29 October 2010 |
21-Year Long-term Follow-up Study Demonstrates Significant Survival Advantage with Betaferon Treatment
|
18 October 2010 |
Bayer's Xarelto® Recognised with 2010 International Prix Galien Award
|
07 October 2010 |
Bayer's Rivaroxaban Successfully Meets Primary Efficacy Outcome
|
01 September 2010 |
Bayer increases sales and earnings in the second quarter
|
30 July 2010 |
Bayer Schering Pharma enters strategic partnership with Hospital in China
|
19 July 2010 |
Bayer Schering Pharma and OncoMed Pharmaceuticals Enter Strategic Alliance
|
18 June 2010 |
Trial of Nexavar® in First-Line Advanced Non-Small Cell Lung Cancer Does Not Meet Primary Endpoint
|
14 June 2010 |
Bayer Schering Pharma Enhances U.S. Research Strategy with New Innovation Center
|
18 May 2010 |
Bayer receives approval for its new oral contraceptive in the U.S.
|
17 May 2010 |
Bayer Schering Pharma Initiates Phase III Trial of Regorafenib
|
10 May 2010 |
Bayer Schering Pharma Initiates Phase III Trial of Regorafenib (BAY 73-4506)
|
10 May 2010 |
Bayer Schering Pharma and EndoCeutics Enter into a Global Agreement
|
06 May 2010 |
Bayer achieves strong gains in sales and earnings
|
30 April 2010 |
Bayer HealthCare Marks 2010 World Hemophilia Day with EUR 250,000 Contribution
|
19 April 2010 |
Bayer to Discontinue Phase II Clinical Trial for Long-Acting Recombinant Factor VIII
|
26 January 2010 |
Bayer to discontinue the LIPLONG study
|
26 January 2010 |
Bayer starts pivotal Phase III trial with Florbetaben
|
01 December 2009 |
Bayer Starts Phase III Trial with Florbetaben
|
01 December 2009 |